Added to YB: 2025-06-18
Pitch date: 2025-06-16
INMB [bullish]
INmune Bio, Inc.
-74.94%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Market Cap
$50.5M
Pitch Price
$8.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.44
P/E
-0.76
EV/Sales
351.78
Sector
Biotechnology
Category
special_situation
INmune Bio: Imminent Phase 2 Alzheimer's Readout of Unique Asset Presents Interesting Speculative Opportunity
INMB: XPro1595 Phase 2 Alzheimer's data imminent. Selective TNF inhibitor blocks soluble TNF (pro-inflammatory) while sparing transmembrane TNF (anti-inflammatory/reparative). P1b showed promising biomarker improvements. Trial enriched for inflammatory patients. If XPro halts cognitive decline while placebo worsens by 0.6 CDR-SB points, should hit significance. Two P1b patients saw dramatic recovery, still stable 3+ years later.
Read full article (20 min)